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Abstract: A 50 year old male HIV patient on antiretroviral therapy was admitted for chest pain. Upon admission, the patient was found 
to have elevated cardiac enzymes, acute thrombocytopenia, hemolytic anemia, acute pancreatitis and acute renal failure. The patient was 
diagnosed with thrombotic thrombocytopenic purpura/haemolytic uremic syndrome and emergency plasma exchange therapy was initi-
ated along with aspirin, beta-blockers, steroids, and antiretroviral therapy. Patient responded well and demonstrated complete resolution 
of ischemic cardiomyopathy with left ventricular ejection fraction improving from 35% to 55% by the time of discharge. Essentially, 
prompt diagnosis and treatment can reverse cardiac damage induced by thrombotic thrombocytopenic purpura.
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Introduction
While  coronary  artery  thrombosis  in  thrombotic 
thrombocytopenic purpura (TTP) has been   established 
in multiple autopsy studies, myocardial infarction as 
TTP’s primary presentation has rarely been reported. 
Cardiologists and physicians must be aware of this 
rare  cardiac  complication  of TTP,  as  any  delay  in 
diagnosis or treatment of this manifestation can be 
lethal. To our knowledge, complete recovery of isch-
emic heart failure in TTP has never been reported.
case Report
A 50 year old African-American male HIV patient 
  presented  to  the  emergency  department  with  com-
plaints of chest pain and shortness of breath for one 
week. He described his chest pain as a pressure like 
sensation which was substernal, non-radiating, wors-
ening  with  exercise  and  associated  with  dyspnea. 
He  had  no  complaints  of  diaphoresis  or  vomiting. 
His shortness of breath progressively worsened over 
the week ultimately resulting in the patient becom-
ing dyspneic with minimal exertion. Patient had no 
fevers, cough, leg swelling, or palpitations.
Patient  was  known  to  have  HIV  and  was  on 
HAART therapy with fosamprenavir 1400 mg twice 
daily,  tenofovir  300  mg  once  daily,  emtricitabine 
200 mg once daily and mycobutin 150 mg once daily. 
Figure 1. electrocardiogram showing a sinus rhythm with normal p-waves and pr interval, a normal axis, normal width of QrS complex, with no ST or 
T wave changes.
Patient was taking metoprolol 25 mg twice daily for 
hypertension. There was no family history of coro-
nary artery disease, and patient was a non-smoker and 
non-alcoholic. At presentation, patient had a blood 
pressure of 152/99 mm of Hg, heart rate of 115/min, 
respiratory rate of 18/min, and was breathing com-
fortably with no distress with an oxygen saturation of 
100% on room air. Physical examination was within 
normal limits, revealed no signs of heart failure, and 
no evident splenomegaly or rash.
Electrocardiogram showed sinus tachycardia with 
no ST or T wave changes (Fig. 1). Upon   admission, 
labs  showed  hemoglobin  7.4  gm/dl,  RBC  count 
2.46 Mil/mm3, platelet count 9,000/mm3, prothrom-
bin  time  11  sec,  reticulocyte  count  5.96%,  serum 
  creatinine  2.9  mg/dl,  LDH  1391  U/L,  haptoglobin 
15 mg/dl, amylase 581 U/L, lipase 257 U/L, troponin 
1.85 ng/ml, and CKMB 4.0 ng/ml. Peripheral blood 
smear showed marked hypochromia,   poikilocytosis, 
anisocytosis, few schistocytes, few helmet cells, and 
slight stippling. Transthoracic echocardiogram showed 
a decreased left ventricular ejection fraction (LVEF) 
of 35%, with moderate diffuse left ventricular hypoki-
nesis, and had no regional wall motion abnormalities. 
Further workup showed CD4 count of 381 cells/mm3. 
Antiphospholipid antibodies were negative, ANA was 
negative and HIT antibodies were negative.TTp and cardiomyopathy
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Patient was diagnosed with thrombotic thrombo-
cytopenic purpura/hemolytic uremic syndrome, fur-
ther  complicated  by  non-ST  elevation  myocardial 
infarction (NSTEMI), and acute pancreatitis based on 
the  peripheral  smear,  thrombocytopenia,    hemolytic 
anemia, acute renal failure, elevated   cardiac biomark-
ers and elevated pancreatic enzymes. An emergency 
Udall Catheter was placed in the patient’s femoral 
vein and plasma exchange therapy was initiated. To 
decrease anemia induced high output heart failure, 
he was transfused with three units of packed RBC’s. 
Also, his current home medications including HAART 
regimen and metoprolol were initiated.
Patient underwent plasma exchange therapy seven 
times during the course of hospital stay. He was also 
started on prednisone 60 mg once daily and, after platelet 
counts were more than 20,000/ml, aspirin 325 mg per day 
was  started  for  an  added  therapeutic  benefit.  Plasma 
exchange therapy was stopped after platelet counts were 
stabilized and   hemolysis resolved. The aforementioned 
were evidenced by low LDH levels and stable hemoglo-
bin. Acute   pancreatitis and renal failure also resolved. At 
the time of discharge, patient had a stable hemoglobin 
of 11.6 gm/dl, platelet count of 180,000/ml, and LDH of 
183 U/L. Repeat transthoracic echocardiogram showed 
complete recovery of left ventricular function with a nor-
mal LVEF% of 55%–65% and patient had no symptoms 
of heart   failure. Patient was discharged after 14 days of 
hospitalization on a tapering regimen of prednisone, along 
with aspirin, metoprolol and HAART therapy. At 3 month 
outpatient follow-up, patient had stable   hemoglobin of 
14 gm/dl and platelet count of 188,000/ml. An out patient 
exercise stress test was normal, suggesting no significant 
coronary artery disease.
Discussion
Coronary  artery  thrombosis  in  thrombotic  throm-
bocytopenic purpura (TTP) has been established in 
multiple autopsy studies, but TTP presenting primar-
ily with cardiac symptoms has rarely been reported.1 
Furthermore,  treating  myocardial  infarction  in  this 
subset of thrombocytopenic patients with antiplatelet 
agents like aspirin and clopidogrel has an increased 
risk of bleeding. Also, the role of beta blockers, ACE 
inhibitors  and  statins  are  less  defined  in  this  rare 
entity. Our experience with this HIV patient showed 
early  diagnosis  and  initiation  of  plasma  exchange 
therapy, along with aspirin, prednisone, metoprolol 
and  HAART  regimen  can  reverse  this  ischemic 
  cardiomyopathy. Severe anemia can cause high out-
put heart failure and hence prompt blood transfusion 
was given to decrease the workload on the heart.
Thrombocytopenia  is  the  result  of  decreased 
bone marrow production, increased sequestration in 
spleen, or increased utilization in the form of   platelet 
  aggregation.  Evaluation  of  acute  thrombocytope-
nia is challenging and requires a careful approach 
in an attempt to exclude fulminant conditions like 
DIC  (disseminated  intravascular  coagulation)  and 
TTP.  Normal  prothrombin  time  in  a  thrombocy-
topenic patient will exclude DIC and the findings of 
  hemolytic anemia will guide in the diagnosis of TTP.2 
Findings of hemolytic anemia include   schistocytes 
on peripheral smear, elevated LDH, low haptoglobin, 
elevated  reticulocyte  count  and  elevated  unconju-
gated bilirubin. Hemolytic uremic syndrome (HUS) 
is considered if the patient also has prominent renal 
failure. Other less serious causes of thrombocytope-
nia include infections, organ transplantation, certain 
drugs and cancers. Among infections, HIV causing 
TTP has been reported extensively before the intro-
duction  of  HAART  therapy.3  Lately,  TTP  in  HIV 
patients is reported rarely with advanced HIV disease, 
and isolated thrombocytopenia needs to be differenti-
ated from TTP in these cases.
TTP/HUS is common among women and blacks. 
TTP  causes  systemic  microvascular  platelet  clots 
leading to ischemia in multiple organs thereby affect-
ing the kidneys, gastrointestinal tract, brain and, in 
rare cases, the heart. The classic pentad of features 
including  fever,  thrombocytopenia,  hemolytic  ane-
mia, neurological abnormalities and renal failure is no 
longer needed to conclude upon a diagnosis of TTP. 
TTP is classified as congenital, acquired idiopathic 
and secondary TTP. The main pathogenesis in TTP is 
the presence of “unusually large Von Willibrand fac-
tor, VWF” with resultant pathological platelet aggre-
gation. These unusually large VWF’s are produced 
by   endothelial cells and platelets, which are normally 
broken down into smaller subunits by a metallopro-
teinase enzyme called ADAMTS13.   Congenital defi-
ciency or   inhibitory IgG antibodies to ADAMTS13 
can lead to   abnormal accumulation of large VWF and 
  aggregation of platelets.4,5Gaddam et al
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However, low ADAMTS13 levels are more spe-
cific  for  congenital  and  idiopathic  TTP  while  vari-
able ADAMTS13 levels are found in secondary TTP. 
  Secondary TTP from HIV, as seen in our patient, is most 
likely from endothelial damage by HIV infection caus-
ing abnormal release of VWF and increased clearance of 
ADAMTS13. Studies conducted on HIV patients with 
TTP showed variable levels of ADAMTS13   levels and 
autoantibodies,   indicating a potentially different patho-
genesis behind TTP in the HIV population.7,8 We did 
not measure an ADAMTS13 level in our patient as it 
is not yet a standard investigation protocol and clinical 
usefulness of ADAMTS13 assays and IgG antibody 
measurements needs further studies.6
Mortality from TTP has decreased from 90% to 
less than 20% due to the initiation of plasma exchange 
therapy.9,10 Plasma exchange therapy  includes  plas-
mapheresis  and  infusion  of  fresh  frozen  plasma. 
  Plasmapheresis  helps  in  removing  unusually  large 
VWF  and  autoantibodies  against  ADAMTS13. 
  Infusion of fresh frozen plasma may add ADAMTS13 
enzyme to the blood. Mortality will be high in patients 
with delayed diagnosis or delayed initiation of   therapy. 
  Complications from plasma exchange include sepsis 
from catheter related local infections, bleeding dur-
ing catheter insertion due to low platelet count and 
rare transfusion reactions.11 Plasma exchange therapy 
should be continued until platelet counts are   stabilized 
and there are no signs of hemolysis.
Addition of antiplatelet agents like ASA in throm-
bocytopenia causes an increased risk of bleeding, but 
trials have shown that ASA is beneficial in prevent-
ing  platelet  aggregation  and  will  improve  mortali-
ty.12 The role of adding clopidogrel into the treatment 
regimen of myocardial infarction in TTP is debatable 
because clopidogrel by itself can cause TTP in some 
rare   cases.13 Steroids have been used for a long time 
in TTP and they are thought to act by decreasing the 
autoantibody production. There are no major studies 
indicating the benefits of adding steroids to plasma 
exchange therapy. But literature review justifies the 
use of steroids and suggests continuing steroids until 
recovery.   Steroids should be used with caution in HIV 
patients, as they might increase the chance of oppor-
tunistic infections. In selected patients, immunosup-
pressive  drugs  like  vincristine,  cyclophosphamide 
or azathioprine are used. HIV patients have a higher 
incidence of TTP and it has been suggested that HIV 
can  cause  TTP.8  Continuation  of  HAART  therapy 
plays a crucial rule in these patients and relapses have 
occurred in patients who discontinued HAART ther-
apy after recovery.14
In conclusion, TTP in HIV with cardiac involve-
ment should be promptly diagnosed and treated with 
plasma exchange therapy, steroids, ASA, metoprolol 
and HAART therapy. Early initiation of therapy in 
cardiac involvement can reduce mortality and reverse 
ischemic cardiomyopathy.
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